Why Toast Stock Is Popping Up Today

Toast, Inc. (NYSE: TOST) shares are trading higher Wednesday after the company reported mixed second-quarter financial results and issued guidance above estimates.

Toast, Inc. (NYSE:TOST) shares are trading higher Wednesday after the company reported mixed second-quarter financial results and issued guidance above estimates.

The Details:

Toast reported a loss of 19 cents per share, missing estimates of a loss of 14 cents per share. The company also reported quarterly sales of $978.00 million, beating the consensus estimate of $939.07 million. Toast issued third-quarter revenue guidance between $1.01 billion and $1.04 billion and fiscal-year 2023 revenue guidance of between $3.81 billion and $3.87 billion.

“Toast delivered record results in the second quarter. In addition to exceeding $1B in ARR, Toast reached Adjusted EBITDA profitability and positive free cash flow for the first time since IPO as we remain focused on driving lean, durable growth,” said Toast CEO Chris Comparato.

On Wednesday, Piper Sandler analyst Brent Bracelin maintained Toast with an Overweight and raised the TOST price target from $23 to $27.

Credit Suisse analyst Timothy Chiodo also maintained Toast with a Neutral and raised the price target from $23 to $25.

Shares of TOST are moving higher on above-average trading volume. According to data from Benzinga Pro, more than 7 million  shares have been traded in the session, compared to the stock’s 100-day average of 7.879 million shares.

Related News: Why WeWork Stock Is Tumbling Wednesday

TOST Price Action: According to Benzinga Pro, Toast shares are trading 19.3% higher at $24.13 at the time of publication.

Image: CordMediaDigitalServices from Pixabay

Total
0
Shares
Related Posts
Read More

Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 womenPivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrollingOvaprene has the potential to be the

DARE

Read More

This Week’s Scheduled IPOs

With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.

IVP